These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11498390)

  • 41. Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials.
    Mross K
    Drug Resist Updat; 2000 Aug; 3(4):223-235. PubMed ID: 11498390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Mancuso A; Sternberg CN
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-angiogenic drugs: from bench to clinical trials.
    Quesada AR; Muñoz-Chápuli R; Medina MA
    Med Res Rev; 2006 Jul; 26(4):483-530. PubMed ID: 16652370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small molecules in anti-angiogenic therapy.
    Giavazzi R; Nicoletti MI
    Curr Opin Investig Drugs; 2002 Mar; 3(3):482-91. PubMed ID: 12054101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-angiogenic therapy: Prospects for treatment of ocular tumors.
    Rosenblatt MI; Azar DT
    Semin Ophthalmol; 2006; 21(3):151-60. PubMed ID: 16912013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospects for therapeutic inhibition of neuroblastoma angiogenesis.
    Shusterman S; Maris JM
    Cancer Lett; 2005 Oct; 228(1-2):171-9. PubMed ID: 15927358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the biology of angiogenesis: review of the most important molecular mechanisms.
    Otrock ZK; Mahfouz RA; Makarem JA; Shamseddine AI
    Blood Cells Mol Dis; 2007; 39(2):212-20. PubMed ID: 17553709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
    Morabito A; Sarmiento R; Bonginelli P; Gasparini G
    Crit Rev Oncol Hematol; 2004 Feb; 49(2):91-107. PubMed ID: 15012971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neoplasms and angiogenesis].
    Lewy-Trenda I
    Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.